logo
THIS fibre mimics ozempic and can help in dramatic weight loss

THIS fibre mimics ozempic and can help in dramatic weight loss

Time of India2 days ago

We've heard about Ozempic, the diabetes drug making waves for its dramatic weight loss effects. But what if something as simple as a fiber found in oats and barley could offer similar benefits—naturally?
That's the idea behind new research from the University of Arizona and the University of Vienna, which suggests a particular kind of fiber—beta-glucan—might help with weight loss and blood sugar control in ways that mimic Ozempic, without the medication.
For years, fiber has taken a backseat in nutrition discussions, overshadowed by protein and carbs. But in recent times, it's making a serious comeback, especially as scientists continue to discover how important it is for our gut health.
Our digestive system is home to trillions of bacteria, often referred to as the gut microbiome. These microbes feed primarily on fiber, and in return, they help regulate everything from digestion to immune function.
Now, researchers are starting to uncover how specific types of fiber might also play a role in managing weight. In the 2024 study, researchers fed various fiber supplements to mice on a high-fat diet. These included common fiber types like wheat dextrin, pectin, resistant starch, and cellulose.
Surprisingly, only one fiber stood out—beta-glucan.
Mice that consumed beta-glucan lost weight and body fat within just a few weeks, while the others didn't see those benefits, even though their gut bacteria changed.
That's an important distinction: it's not just about feeding your gut—it's about feeding it the right kind of fiber.
What makes 'Beta-Glucan' special?
Beta-glucan is a soluble fiber, meaning it dissolves in water and can be easily fermented by gut bacteria. It's naturally found in whole grains like oats and barley—foods you probably already have in your pantry.
In the study, mice that ate beta-glucan developed higher levels of a beneficial gut bacterium called
Ileibacterium
, which other studies have already linked to weight loss.
These mice didn't even reduce their food intake, but they still lost weight—because their metabolism changed.
One key change? The production of a gut chemical called butyrate, which is made when bacteria digest fiber. Butyrate helps trigger the release of GLP-1, the same appetite-suppressing hormone that Ozempic is designed to mimic.
So in essence, eating more beta-glucan may help your body naturally produce GLP-1, helping regulate your appetite and blood sugar without the need for medication.
More than just weight loss
But the benefits don't stop there. Butyrate may also improve gut lining health, support liver function, and reduce inflammation. Scientists believe there's still more to uncover about how these compounds work together to support weight management and overall wellness.
However, it's important to note: this research was done in mice. While the results are promising, human trials are still needed to confirm whether beta-glucan works the same way in people.
Sources of Beta-Glucan
Beta-glucan slows the passage of food in the intestine. This increases the time taken by the body to digest food, which in turn keeps you full for a longer time. And they are also easily available naturally. Here are a few foods that you can include in your daily diet
oats
barley
sorghum
rye
maize
triticale
wheat
durum wheat
rice
mushrooms
seaweed
One step to a healthier you—join Times Health+ Yoga and feel the change

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

One more death takes Covid toll to eight; active cases surge to 1,435 in Kerala
One more death takes Covid toll to eight; active cases surge to 1,435 in Kerala

New Indian Express

time3 hours ago

  • New Indian Express

One more death takes Covid toll to eight; active cases surge to 1,435 in Kerala

T'PURAM/PATHANAMTHITTA : Kerala's latest Covid toll rose to eight as one more person died of the infection on Monday. Meanwhile, 35 new cases took the state's active case-load to 1,435, even as Health Minister Veena George attributed the surge to the state's commitment to accurate and widespread testing. With the latest deaths, Kerala's cumulative Covid death toll stands at 72,147 since the pandemic began. There have been 32 Covid-related deaths in the country this year, with the majority occurring after the surge in May. Before May 19, Kerala had reported just one death due to the virus. Health officials said most of the deceased had underlying health conditions. The current surge in cases is being attributed to the rapidly spreading Omicron JN.1 sub-lineages, especially LF.7 and NB.1.8. Surveillance was ramped up in the state after a spike in cases was observed in Southeast Asian countries at the end of April. The health department has made masks mandatory in hospitals and for healthcare workers. A few private hospitals have set up dedicated wards and ICU wings exclusively for Covid patients to prevent cross-infection. A screening process has been introduced for symptomatic individuals, especially those in high-risk categories. Speaking to reporters on the sidelines of the district Praveshanotsavam in Pathanamthitta, Veena attributed the rise in cases to the state's accuracy in Covid testing. 'Testing is being done and the numbers are being recorded accurately. So, there is no need to worry. We are monitoring the situation very closely,' she said. The minister said in view of the global surge in Covid cases, Kerala has ramped up testing. 'As a result, we are witnessing a spike in the number of cases. Other places have not initiated testing yet,' she said. Though the variant appears to be less severe, its potential for spread remains high, Veena noted while urging people to take precaution, including wearing masks. The health department has instructed district medical officers to monitor different areas for potential outbreaks and implement preventive measures. Veena stressed that those with pre-existing illnesses should take extra precautions, including wearing of masks, as Covid poses a greater risk to them. The minister also urged the people to avoid unnecessary hospital visits and reminded healthcare workers to strictly adhere to infection control protocols. matic individuals, especially

Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial
Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial

Mint

time14 hours ago

  • Mint

Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial

Mumbai: Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, on Monday shared promising results from an ongoing phase-1 trial of ISB 2001, a novel drug targeting relapsed or refractory multiple myeloma. The data, presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), showed an overall response rate (ORR) of 74% in heavily pre-treated patients. Refractory multiple myeloma refers to cases where the cancer does not respond or stops responding to treatment. Multiple myeloma is a rare, incurable blood cancer affecting plasma cells. While several therapies have been approved in recent years, most patients eventually relapse or become resistant, leaving limited treatment options. ISB 2001 is being developed by IGI to address this unmet need, particularly in patients who have previously received T-cell–based therapies such as CAR T-cells or bispecific antibodies. It is a first-in-class tri-specific antibody designed to simultaneously target BCMA, CD38, and CD3—three proteins associated with multiple myeloma. The drug aims to overcome resistance mechanisms seen with earlier-generation immunotherapies, while minimizing off-tumour toxicity. The phase-1 trial, known as TRIgnite-1, is evaluating the drug's safety and efficacy in patients who have exhausted standard treatment options. The latest data, from the full dose-escalation phase, covered 35 patients with a median of six prior lines of therapy. The overall response rate was 74%. 'The high response rates and low safety concerns demonstrated in the dose-escalation portion of the TRIgnite-1 study, conducted in a heavily pre-treated population across multiple types of therapies, reinforce the promise of ISB 2001 as a potential new treatment for patients,' said Lida Pacaud, M.D., chief medical officer at IGI. 'As we advance to the second part of the TRIgnite-1 study, our focus is now on defining the recommended dosing schedule and evaluating ISB 2001 in a larger population of heavily pre-treated RRMM patients, where we hope to observe similarly impressive treatment responses and tolerability,' Pacaud said. Among patients receiving higher, active dose levels (≥50 µg/kg), the ORR rose to 79%, with 30% achieving complete or stringent complete responses. Patients who had not previously received T-cell–based treatments saw an ORR of 84%. Even among those with prior exposure to CAR T or CD38-targeted therapies, response rates remained strong, ranging from 71% to 73%. The safety profile of ISB 2001 was favourable, with no dose-limiting toxicities reported. The most common side effect was cytokine release syndrome (CRS), seen in 69% of patients—mostly mild (Grade 1), with only four cases classified as moderate (Grade 2). There were no severe neurological adverse events. The market for multiple myeloma is projected to grow to about $33 billion by 2030, according to estimates by Bloomberg Intelligence. The trial has now entered its dose-expansion phase, which will determine the recommended Phase 2 dose and optimal dosing schedule. ISB 2001 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2023 and recently received Fast Track status, underscoring the agency's recognition of its potential.

DHSE Kerala Plus One (+1) Result 2025, Keralaresults.nic.in: HSE result out, 62.28% students pass
DHSE Kerala Plus One (+1) Result 2025, Keralaresults.nic.in: HSE result out, 62.28% students pass

Indian Express

time18 hours ago

  • Indian Express

DHSE Kerala Plus One (+1) Result 2025, Keralaresults.nic.in: HSE result out, 62.28% students pass

DHSE Kerala Plus One (+1) Result 2025 Direct Link OUT at The results for the Higher Secondary (DHSE) and Vocational Higher Secondary (VHSE) Plus One examinations have been announced today on the official website. Students can access their scorecards through any of the following official websites at and DHSE Kerala Plus One (+1) Result 2025, LIVE The Kerala +1 Exams 2025 were conducted from March 6 to March 9, 2025, across various centres in the state. Last year, the directorate declared the Kerala +1 results on May 28. Students can take more information on supplementary results and other additional information from As per the data, a total of 3,83,647 students from school-going regular categories registered for the exam across Science, Humanities, and Commerce streams. Additionally, 28,177 candidates were registered under the Open School stream, while 1,572 candidates registered for the Technical stream. Out of the school-going regular students, 3,79,444 candidates' marks were tabulated, and the overall pass percentage (students scoring above 30%) stood at 62.28% in 2025. For Open School students, 27,295 marks were tabulated, with a lower overall pass percentage of 40.53%. Meanwhile, in the Technical stream, 1,562 candidates had their marks tabulated, and 44.37% of them passed. Among regular school-going candidates, the Science stream had the highest number of registered students at 1,90,383, with 1,89,479 marks tabulated and a pass percentage of 68.69%. The Commerce stream followed, with 1,12,647 students registered and 59.64% passing. The Humanities stream had the lowest pass percentage at 50.57%, with 80,617 students registered. In the Open School category, Science students recorded a 70.36% pass rate—the highest among all categories, despite having only 3,335 registrations. Humanities and Commerce in Open School lagged behind with 37.30% and 35.31% pass rates, respectively. For the Technical stream, 1,562 marks were recorded and 693 candidates scored above 30 marks, bringing the pass rate to 44.37%. Compared to last year, there has been a visible dip in performance across all categories. Last year, the overall pass percentage for school-going regular students was 67.30%, which has dropped to 62.28% in 2025. Similarly, the Open School category saw a marginal decline from 40.73% in 2024 to 40.53% this year. Stream-wise, the Science stream for school-going students had a pass percentage of 69.98% last year, slightly higher than this year's 68.69%. Commerce dropped from 69.20% to 59.64%, and Humanities declined from 57.96% to 50.57%.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store